Radical Cystectomy Compared to Combined Modality Treatment for Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis

To perform a comprehensive comparison of overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), and treatment-related complications between radical cystectomy (RC) and combined modality treatment (CMT—radiation therapy, concurrent chemotherapy, and maximal transuret...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of radiation oncology, biology, physics Vol. 97; no. 5; pp. 1002 - 1020
Main Authors Vashistha, Vishal, Wang, Hanzhang, Mazzone, Andrew, Liss, Michael A., Svatek, Robert S., Schleicher, Mary, Kaushik, Dharam
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.04.2017
Subjects
Online AccessGet full text

Cover

Loading…
Abstract To perform a comprehensive comparison of overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), and treatment-related complications between radical cystectomy (RC) and combined modality treatment (CMT—radiation therapy, concurrent chemotherapy, and maximal transurethral resection of bladder tumor) in the setting of muscle-invasive bladder cancer. We searched 7 databases (PubMed, Scopus, EMBASE, Proquest, CINAHL, and ClinicalTrials.gov) for randomized, controlled trials and prospective and retrospective studies directly comparing RC with CMT from database inception to March 2016. We conducted meta-analyses evaluating OS, DSS, and PFS with hazard ratios (HRs) and 95% confidence intervals (CIs). Nineteen studies evaluating 12,380 subjects were selected. For the 8 studies encompassing 9554 subjects eligible for meta-analyses, we found no difference in OS at 5 years (HR 0.96, favoring CMT, 95% CI 0.72-1.29; P=.778) or 10 years (HR 1.02, favoring cystectomy, 95% CI 0.73-1.42; P=.905). No difference was observed in DSS at 5 years (HR 0.83, favoring radiation, 95% CI 0.54-1.28; P=.390) or 10 years (HR 1.17, favoring cystectomy, 95% CI 0.89-1.55; P=.264), or PFS at 10 years (HR 0.85, favoring CMT, 95% CI 0.43-1.67; P=.639). The cystectomy arms had higher rates of early major complications, whereas rates of minor complications were similar between the 2 treatments. Current meta-analysis reveals no differences in OS, DSS, or PFS between RC and CMT. Further randomized, controlled trials are necessary to identify the optimal treatment for specific patients.
AbstractList To perform a comprehensive comparison of overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), and treatment-related complications between radical cystectomy (RC) and combined modality treatment (CMT—radiation therapy, concurrent chemotherapy, and maximal transurethral resection of bladder tumor) in the setting of muscle-invasive bladder cancer. We searched 7 databases (PubMed, Scopus, EMBASE, Proquest, CINAHL, and ClinicalTrials.gov) for randomized, controlled trials and prospective and retrospective studies directly comparing RC with CMT from database inception to March 2016. We conducted meta-analyses evaluating OS, DSS, and PFS with hazard ratios (HRs) and 95% confidence intervals (CIs). Nineteen studies evaluating 12,380 subjects were selected. For the 8 studies encompassing 9554 subjects eligible for meta-analyses, we found no difference in OS at 5 years (HR 0.96, favoring CMT, 95% CI 0.72-1.29; P=.778) or 10 years (HR 1.02, favoring cystectomy, 95% CI 0.73-1.42; P=.905). No difference was observed in DSS at 5 years (HR 0.83, favoring radiation, 95% CI 0.54-1.28; P=.390) or 10 years (HR 1.17, favoring cystectomy, 95% CI 0.89-1.55; P=.264), or PFS at 10 years (HR 0.85, favoring CMT, 95% CI 0.43-1.67; P=.639). The cystectomy arms had higher rates of early major complications, whereas rates of minor complications were similar between the 2 treatments. Current meta-analysis reveals no differences in OS, DSS, or PFS between RC and CMT. Further randomized, controlled trials are necessary to identify the optimal treatment for specific patients.
Purpose To perform a comprehensive comparison of overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), and treatment-related complications between radical cystectomy (RC) and combined modality treatment (CMT—radiation therapy, concurrent chemotherapy, and maximal transurethral resection of bladder tumor) in the setting of muscle-invasive bladder cancer. Methods and Materials We searched 7 databases (PubMed, Scopus, EMBASE, Proquest, CINAHL, and ClinicalTrials.gov ) for randomized, controlled trials and prospective and retrospective studies directly comparing RC with CMT from database inception to March 2016. We conducted meta-analyses evaluating OS, DSS, and PFS with hazard ratios (HRs) and 95% confidence intervals (CIs). Results Nineteen studies evaluating 12,380 subjects were selected. For the 8 studies encompassing 9554 subjects eligible for meta-analyses, we found no difference in OS at 5 years (HR 0.96, favoring CMT, 95% CI 0.72-1.29; P =.778) or 10 years (HR 1.02, favoring cystectomy, 95% CI 0.73-1.42; P =.905). No difference was observed in DSS at 5 years (HR 0.83, favoring radiation, 95% CI 0.54-1.28; P =.390) or 10 years (HR 1.17, favoring cystectomy, 95% CI 0.89-1.55; P =.264), or PFS at 10 years (HR 0.85, favoring CMT, 95% CI 0.43-1.67; P =.639). The cystectomy arms had higher rates of early major complications, whereas rates of minor complications were similar between the 2 treatments. Conclusion Current meta-analysis reveals no differences in OS, DSS, or PFS between RC and CMT. Further randomized, controlled trials are necessary to identify the optimal treatment for specific patients.
To perform a comprehensive comparison of overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), and treatment-related complications between radical cystectomy (RC) and combined modality treatment (CMT-radiation therapy, concurrent chemotherapy, and maximal transurethral resection of bladder tumor) in the setting of muscle-invasive bladder cancer.PURPOSETo perform a comprehensive comparison of overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), and treatment-related complications between radical cystectomy (RC) and combined modality treatment (CMT-radiation therapy, concurrent chemotherapy, and maximal transurethral resection of bladder tumor) in the setting of muscle-invasive bladder cancer.We searched 7 databases (PubMed, Scopus, EMBASE, Proquest, CINAHL, and ClinicalTrials.gov) for randomized, controlled trials and prospective and retrospective studies directly comparing RC with CMT from database inception to March 2016. We conducted meta-analyses evaluating OS, DSS, and PFS with hazard ratios (HRs) and 95% confidence intervals (CIs).METHODS AND MATERIALSWe searched 7 databases (PubMed, Scopus, EMBASE, Proquest, CINAHL, and ClinicalTrials.gov) for randomized, controlled trials and prospective and retrospective studies directly comparing RC with CMT from database inception to March 2016. We conducted meta-analyses evaluating OS, DSS, and PFS with hazard ratios (HRs) and 95% confidence intervals (CIs).Nineteen studies evaluating 12,380 subjects were selected. For the 8 studies encompassing 9554 subjects eligible for meta-analyses, we found no difference in OS at 5 years (HR 0.96, favoring CMT, 95% CI 0.72-1.29; P=.778) or 10 years (HR 1.02, favoring cystectomy, 95% CI 0.73-1.42; P=.905). No difference was observed in DSS at 5 years (HR 0.83, favoring radiation, 95% CI 0.54-1.28; P=.390) or 10 years (HR 1.17, favoring cystectomy, 95% CI 0.89-1.55; P=.264), or PFS at 10 years (HR 0.85, favoring CMT, 95% CI 0.43-1.67; P=.639). The cystectomy arms had higher rates of early major complications, whereas rates of minor complications were similar between the 2 treatments.RESULTSNineteen studies evaluating 12,380 subjects were selected. For the 8 studies encompassing 9554 subjects eligible for meta-analyses, we found no difference in OS at 5 years (HR 0.96, favoring CMT, 95% CI 0.72-1.29; P=.778) or 10 years (HR 1.02, favoring cystectomy, 95% CI 0.73-1.42; P=.905). No difference was observed in DSS at 5 years (HR 0.83, favoring radiation, 95% CI 0.54-1.28; P=.390) or 10 years (HR 1.17, favoring cystectomy, 95% CI 0.89-1.55; P=.264), or PFS at 10 years (HR 0.85, favoring CMT, 95% CI 0.43-1.67; P=.639). The cystectomy arms had higher rates of early major complications, whereas rates of minor complications were similar between the 2 treatments.Current meta-analysis reveals no differences in OS, DSS, or PFS between RC and CMT. Further randomized, controlled trials are necessary to identify the optimal treatment for specific patients.CONCLUSIONCurrent meta-analysis reveals no differences in OS, DSS, or PFS between RC and CMT. Further randomized, controlled trials are necessary to identify the optimal treatment for specific patients.
Author Vashistha, Vishal
Liss, Michael A.
Kaushik, Dharam
Wang, Hanzhang
Mazzone, Andrew
Svatek, Robert S.
Schleicher, Mary
Author_xml – sequence: 1
  givenname: Vishal
  surname: Vashistha
  fullname: Vashistha, Vishal
  organization: Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio
– sequence: 2
  givenname: Hanzhang
  surname: Wang
  fullname: Wang, Hanzhang
  organization: Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas
– sequence: 3
  givenname: Andrew
  surname: Mazzone
  fullname: Mazzone, Andrew
  organization: Rush Medical College, Rush University Medical Center, Chicago, Illinois
– sequence: 4
  givenname: Michael A.
  surname: Liss
  fullname: Liss, Michael A.
  organization: Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas
– sequence: 5
  givenname: Robert S.
  surname: Svatek
  fullname: Svatek, Robert S.
  organization: Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas
– sequence: 6
  givenname: Mary
  surname: Schleicher
  fullname: Schleicher, Mary
  organization: Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio
– sequence: 7
  givenname: Dharam
  surname: Kaushik
  fullname: Kaushik, Dharam
  email: Kaushik@uthscsa.edu
  organization: Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28332983$$D View this record in MEDLINE/PubMed
https://www.osti.gov/biblio/22649890$$D View this record in Osti.gov
BookMark eNqVUkuLFDEYDLLiPvQfiAS8eOkxj062exFhHHws7CLszsFbSCdfY8buZDbJjPTdH27aWT0IsnhKQqoqqarvFB354AGh55QsKKHy9WbhNjF02wUrpwWlCyLkI3RCm_O24kJ8OUInhEtS8XJ9jE5T2hBCKD2vn6Bj1nDO2oafoB832jqjB7yaUgaTwzjhVRi3OoLFOcz7zvmyvw5WDy5PeB1B5xF8xn2I-HqXzADVpd_r5PaA3w3aWoh4pb2BeIGX-HYWHnV2Bt_A3sF3rH2Rg6yrpdfDlFx6ih73ekjw7H49Q-sP79erT9XV54-Xq-VVZYSsc9VKoVkvLSPECAFARQu1qGlnaimanoA02jbQM67BkoZ1hPPeFgwxhHWCn6GXB9mQslPJuGL4qwneF9-KMVm3TUsK6tUBtY3hbgcpq9ElA8OgPYRdUrRpSC1b2fICfXEP3XUjWLWNbtRxUr_jLYD6ADAxpBSh_wOhRM0tqo06tKjmFhWlqrRYaBd_0cpfS4LB56jd8BD57YEMJcmSd5ydQmnDujgbtcH9r4AZnJ-H5BtMkDZhF0tvJQiVmCLqdp6yecio5FzUvxJ882-Bh9__Cd5x5Gk
CitedBy_id crossref_primary_10_1371_journal_pone_0216255
crossref_primary_10_5935_2526_8732_20210016
crossref_primary_10_3233_BLC_189037
crossref_primary_10_1177_17588359241249068
crossref_primary_10_36290_uro_2020_042
crossref_primary_10_1186_s13014_023_02338_w
crossref_primary_10_1007_s11912_018_0711_0
crossref_primary_10_1007_s15004_019_6552_7
crossref_primary_10_1016_j_hoc_2021_02_006
crossref_primary_10_1080_02656736_2023_2275540
crossref_primary_10_1007_s00345_018_2606_y
crossref_primary_10_1016_j_urolonc_2019_09_008
crossref_primary_10_1097_COC_0000000000000491
crossref_primary_10_1007_s00761_022_01213_9
crossref_primary_10_1007_s00120_024_02420_5
crossref_primary_10_1093_jrr_rrad027
crossref_primary_10_3390_medicina59010050
crossref_primary_10_1016_j_eururo_2019_01_011
crossref_primary_10_1007_s00761_017_0293_8
crossref_primary_10_1016_j_ajur_2021_10_002
crossref_primary_10_1016_j_clgc_2018_09_021
crossref_primary_10_3390_cancers15010041
crossref_primary_10_1016_j_clgc_2018_09_023
crossref_primary_10_1200_JCO_19_02035
crossref_primary_10_1007_s00066_018_1274_6
crossref_primary_10_1016_j_semradonc_2022_10_005
crossref_primary_10_1186_s13014_023_02348_8
crossref_primary_10_1016_j_clon_2022_05_017
crossref_primary_10_1259_bjr_20200241
crossref_primary_10_1007_s12094_023_03264_9
crossref_primary_10_1016_j_urolonc_2020_11_023
crossref_primary_10_1016_j_canrad_2022_06_009
crossref_primary_10_1097_MOU_0000000000000601
crossref_primary_10_1007_s00345_020_03436_0
crossref_primary_10_1038_s41572_023_00468_9
crossref_primary_10_1093_jrr_rraa039
crossref_primary_10_1080_14712598_2019_1604673
crossref_primary_10_1007_s12094_018_02001_x
crossref_primary_10_1016_j_csbj_2024_10_007
crossref_primary_10_4103_jcrt_jcrt_1661_21
crossref_primary_10_1002_cam4_2126
crossref_primary_10_1016_j_clgc_2021_11_002
crossref_primary_10_1177_0300891618766109
crossref_primary_10_1016_j_urology_2018_07_058
crossref_primary_10_1007_s00066_023_02134_1
crossref_primary_10_1016_S1470_2045_18_30693_4
crossref_primary_10_1016_j_urology_2018_07_060
crossref_primary_10_1016_j_radonc_2022_01_008
crossref_primary_10_1007_s15004_018_6096_2
crossref_primary_10_1016_j_euo_2022_10_003
crossref_primary_10_1016_j_urology_2018_07_061
crossref_primary_10_1080_14737140_2020_1736565
crossref_primary_10_1007_s00120_018_0628_0
crossref_primary_10_1007_s11934_018_0859_z
crossref_primary_10_1016_j_annonc_2021_11_012
crossref_primary_10_3233_BLC_200291
crossref_primary_10_1016_j_urolonc_2020_09_001
crossref_primary_10_15406_ijrrt_2024_11_00407
crossref_primary_10_1007_s00120_023_02194_2
crossref_primary_10_1016_j_canrad_2023_06_011
crossref_primary_10_1007_s12094_022_02815_w
crossref_primary_10_1177_03915603241256009
crossref_primary_10_3322_caac_21631
crossref_primary_10_1007_s13566_018_0347_6
crossref_primary_10_1016_j_ijrobp_2018_12_028
crossref_primary_10_1016_j_ctro_2021_08_001
crossref_primary_10_1016_j_ctro_2021_08_003
crossref_primary_10_1016_j_critrevonc_2021_103235
crossref_primary_10_1016_j_urolonc_2020_10_004
crossref_primary_10_1016_j_urolonc_2020_10_005
crossref_primary_10_1080_0284186X_2022_2101381
crossref_primary_10_1007_s11912_020_0880_5
crossref_primary_10_1016_j_ijrobp_2017_11_040
crossref_primary_10_1097_JU9_0000000000000132
crossref_primary_10_1097_MOU_0000000000001113
crossref_primary_10_1200_EDBK_432054
crossref_primary_10_36106_ijsr_7600504
crossref_primary_10_1016_j_urology_2019_05_062
crossref_primary_10_1007_s11864_020_00800_5
crossref_primary_10_26779_2522_1396_2020_9_10_63
crossref_primary_10_1007_s00120_021_01712_4
crossref_primary_10_1016_j_clon_2021_03_021
crossref_primary_10_1007_s00120_022_01963_9
crossref_primary_10_1016_j_ijrobp_2017_07_002
crossref_primary_10_1016_j_urolonc_2021_05_036
crossref_primary_10_1016_j_ijrobp_2017_07_001
crossref_primary_10_3390_jcm12041560
crossref_primary_10_1200_EDBK_201227
Cites_doi 10.1016/j.juro.2011.09.159
10.3322/caac.21254
10.1016/j.radonc.2009.04.020
10.1111/j.1464-410X.2010.09537.x
10.4103/0973-1482.34684
10.1002/sim.1303
10.1017/S1460396914000107
10.1007/s00345-013-1123-2
10.1016/j.canep.2009.08.008
10.1200/jco.2014.32.4_suppl.334
10.1136/bmj.327.7414.557
10.1016/j.eururo.2005.03.022
10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
10.1016/j.critrevonc.2015.04.006
10.1016/j.clon.2003.10.001
10.1016/j.ijrobp.2009.04.050
10.1080/21681805.1991.12068888
10.1016/j.juro.2011.02.1879
10.1016/S0302-2838(02)00581-X
10.1111/j.1464-410X.1976.tb06705.x
10.1016/j.eururo.2011.11.010
10.1016/j.juro.2015.02.2635
10.1111/j.1464-410X.1989.tb05185.x
10.1016/j.ijrobp.2012.07.211
10.1002/1097-0142(197702)39:2+<973::AID-CNCR2820390737>3.0.CO;2-O
10.1016/S1569-9056(14)60124-X
10.1016/j.eururo.2005.04.006
10.1111/j.1464-410X.2008.07636.x
10.1016/j.asjsur.2014.01.010
10.1097/COC.0b013e318199fb42
10.7326/0003-4819-151-4-200908180-00135
10.4103/0970-1591.38603
10.1016/j.ijrobp.2007.06.030
10.1186/1471-2407-8-250
10.1111/j.1464-410X.1982.tb13537.x
10.1016/j.urolonc.2014.09.014
ContentType Journal Article
Copyright 2016 Elsevier Inc.
Elsevier Inc.
Copyright © 2016 Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2016 Elsevier Inc.
– notice: Elsevier Inc.
– notice: Copyright © 2016 Elsevier Inc. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
OTOTI
DOI 10.1016/j.ijrobp.2016.11.056
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
OSTI.GOV
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE


MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1879-355X
EndPage 1020
ExternalDocumentID 22649890
28332983
10_1016_j_ijrobp_2016_11_056
S0360301616335490
1_s2_0_S0360301616335490
Genre Meta-Analysis
Systematic Review
Journal Article
GroupedDBID ---
--K
.1-
.FO
0R~
1B1
1P~
1RT
1~5
4.4
457
4G.
53G
5RE
7-5
AAEDT
AAEDW
AAQQT
AAWTL
AAXUO
ABJNI
ABLJU
ABNEU
ABOCM
ABUDA
ACGFS
ACIUM
ACVFH
ADBBV
ADCNI
ADVLN
AENEX
AEUPX
AEVXI
AFPUW
AFRHN
AFTJW
AGCQF
AHHHB
AIGII
AITUG
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
BELOY
DU5
EBS
EFKBS
EJD
F5P
FDB
GBLVA
HED
HMO
IHE
J1W
KOM
LX3
M41
MO0
O9-
OC~
OO-
RNS
ROL
RPZ
SDG
SEL
SES
SSZ
UV1
XH2
Z5R
~S-
.55
.GJ
29J
5VS
AALRI
AAQFI
AAQXK
ABEFU
ABWVN
ACRPL
ADMUD
ADNMO
ADPAM
AFCTW
AFFNX
AFJKZ
AGRDE
ASPBG
AVWKF
AZFZN
EFJIC
FEDTE
FGOYB
FIRID
G-2
HMK
HVGLF
HX~
HZ~
NQ-
R2-
RIG
SAE
SEW
UDS
X7M
XPP
ZGI
AAIAV
AGZHU
ALXNB
ZA5
AAYWO
AAYXX
AGQPQ
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ABPTK
OTOTI
ID FETCH-LOGICAL-c564t-965a2f6d200c55ee159e4541bc4658f0e6cad8ef23aed082b033fd9e40c02b53
ISSN 0360-3016
1879-355X
IngestDate Thu May 18 18:35:48 EDT 2023
Fri Jul 11 09:47:51 EDT 2025
Mon Jul 21 05:22:14 EDT 2025
Tue Jul 01 02:23:29 EDT 2025
Thu Apr 24 22:53:43 EDT 2025
Fri Feb 23 02:28:08 EST 2024
Tue Feb 25 20:10:00 EST 2025
Tue Aug 26 16:58:42 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
License Copyright © 2016 Elsevier Inc. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c564t-965a2f6d200c55ee159e4541bc4658f0e6cad8ef23aed082b033fd9e40c02b53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ObjectType-Undefined-4
PMID 28332983
PQID 1880469693
PQPubID 23479
PageCount 19
ParticipantIDs osti_scitechconnect_22649890
proquest_miscellaneous_1880469693
pubmed_primary_28332983
crossref_primary_10_1016_j_ijrobp_2016_11_056
crossref_citationtrail_10_1016_j_ijrobp_2016_11_056
elsevier_sciencedirect_doi_10_1016_j_ijrobp_2016_11_056
elsevier_clinicalkeyesjournals_1_s2_0_S0360301616335490
elsevier_clinicalkey_doi_10_1016_j_ijrobp_2016_11_056
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-04-01
PublicationDateYYYYMMDD 2017-04-01
PublicationDate_xml – month: 04
  year: 2017
  text: 2017-04-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle International journal of radiation oncology, biology, physics
PublicationTitleAlternate Int J Radiat Oncol Biol Phys
PublicationYear 2017
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Miller (bib18) 1977; 39
Sun, Gandaglia, Pierre (bib37) 2014; 32
Siegel, Miller, Jemal (bib1) 2015; 65
Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at
Chamie, Hu, Devere White (bib13) 2008; 102
Accessed November 17, 2016.
Sell, Jakobsen, Nerstrom (bib21) 1991; 138
Wallace, Bloom (bib25) 1976; 48
Azuma, Yamamoto, Inamoto (bib10) 2009; 32
Kalogeras, Lampri, Goussia (bib16) 2008; 13
Parmar, Torri, Stewart (bib5) 1998; 17
Higgins, Thompson, Deeks (bib7) 2003; 327
Eswara, Efstathiou, Heney (bib32) 2012; 187
Gofrit, Nof, Meirovitz (bib14) 2015; 33
Fedewa, Soliman, Ismail (bib30) 2009; 33
Zarzour, Selim, Abd-Elsayed (bib31) 2008; 8
(bib2) 2005; 48
Nieuwenhuijzen, Pos, Moonen (bib20) 2005; 48
Moher, Liberati, Tetzlaff (bib4) 2009; 151
Haresh, Julka, Sharma (bib15) 2007; 3
Munro, Sundaram, Weston (bib19) 2010; 77
Shelley, Wilt, Barber (bib28) 2004; 16
Williamson, Smith, Hutton (bib6) 2002; 21
van der Steen-Banasik, Ploeg, Witjes (bib24) 2009; 93
Arcangeli, Strigari, Arcangeli (bib29) 2015; 95
Yadav, Ghoshal, Sharma (bib26) 2008; 24
Sun, Gandaglia, Larcher (bib38) 2015; 193
Huddart, Hall, Lewis (bib34) 2010; 106
Mameghan, Fisher (bib27) 1989; 63
Supit, Mochtar, Santoso (bib22) 2014; 37
Pokala N, Agarwal P, Kiran RP, et al. Comparative survival following different treatment modalities for stage T2-muscle invasive bladder cancer in octogenarians—a population based study. Presented at the Annual Meeting of the American Urological Association, May 14-19, 2011, Washington, DC.
Chahal, Sundaram, Iddenden (bib12) 2003; 43
Efstathiou, Spiegel, Shipley (bib3) 2012; 61
Kotwal, Choudhury, Johnston (bib17) 2008; 70
Sujenthiran, Van Der Meulen, Kelly (bib36) 2014; 13
AlGizawy, Essa, Abdel-Wanis (bib9) 2014; 13
Bloom, Hendry, Wallace (bib11) 1982; 54
Huddart, Birtle, Lewis (bib33) 2012; 84
Trulson, Sharma, Haden (bib23) 2014; 32
Chahal (10.1016/j.ijrobp.2016.11.056_bib12) 2003; 43
Wallace (10.1016/j.ijrobp.2016.11.056_bib25) 1976; 48
Nieuwenhuijzen (10.1016/j.ijrobp.2016.11.056_bib20) 2005; 48
Zarzour (10.1016/j.ijrobp.2016.11.056_bib31) 2008; 8
Kalogeras (10.1016/j.ijrobp.2016.11.056_bib16) 2008; 13
van der Steen-Banasik (10.1016/j.ijrobp.2016.11.056_bib24) 2009; 93
Huddart (10.1016/j.ijrobp.2016.11.056_bib33) 2012; 84
Eswara (10.1016/j.ijrobp.2016.11.056_bib32) 2012; 187
Gofrit (10.1016/j.ijrobp.2016.11.056_bib14) 2015; 33
Chamie (10.1016/j.ijrobp.2016.11.056_bib13) 2008; 102
Efstathiou (10.1016/j.ijrobp.2016.11.056_bib3) 2012; 61
Azuma (10.1016/j.ijrobp.2016.11.056_bib10) 2009; 32
Haresh (10.1016/j.ijrobp.2016.11.056_bib15) 2007; 3
Fedewa (10.1016/j.ijrobp.2016.11.056_bib30) 2009; 33
Munro (10.1016/j.ijrobp.2016.11.056_bib19) 2010; 77
AlGizawy (10.1016/j.ijrobp.2016.11.056_bib9) 2014; 13
Shelley (10.1016/j.ijrobp.2016.11.056_bib28) 2004; 16
Yadav (10.1016/j.ijrobp.2016.11.056_bib26) 2008; 24
Siegel (10.1016/j.ijrobp.2016.11.056_bib1) 2015; 65
Sun (10.1016/j.ijrobp.2016.11.056_bib38) 2015; 193
Bloom (10.1016/j.ijrobp.2016.11.056_bib11) 1982; 54
Arcangeli (10.1016/j.ijrobp.2016.11.056_bib29) 2015; 95
Trulson (10.1016/j.ijrobp.2016.11.056_bib23) 2014; 32
Mameghan (10.1016/j.ijrobp.2016.11.056_bib27) 1989; 63
Williamson (10.1016/j.ijrobp.2016.11.056_bib6) 2002; 21
Sell (10.1016/j.ijrobp.2016.11.056_bib21) 1991; 138
Sujenthiran (10.1016/j.ijrobp.2016.11.056_bib36) 2014; 13
Moher (10.1016/j.ijrobp.2016.11.056_bib4) 2009; 151
10.1016/j.ijrobp.2016.11.056_bib35
(10.1016/j.ijrobp.2016.11.056_bib2) 2005; 48
Miller (10.1016/j.ijrobp.2016.11.056_bib18) 1977; 39
10.1016/j.ijrobp.2016.11.056_bib8
Kotwal (10.1016/j.ijrobp.2016.11.056_bib17) 2008; 70
Supit (10.1016/j.ijrobp.2016.11.056_bib22) 2014; 37
Huddart (10.1016/j.ijrobp.2016.11.056_bib34) 2010; 106
Higgins (10.1016/j.ijrobp.2016.11.056_bib7) 2003; 327
Sun (10.1016/j.ijrobp.2016.11.056_bib37) 2014; 32
Parmar (10.1016/j.ijrobp.2016.11.056_bib5) 1998; 17
29280469 - Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):757. doi: 10.1016/j.ijrobp.2017.07.001.
29396699 - Strahlenther Onkol. 2018 Apr;194(4):358-359. doi: 10.1007/s00066-018-1274-6.
29280470 - Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):757-758. doi: 10.1016/j.ijrobp.2017.07.002.
References_xml – volume: 16
  start-page: 166
  year: 2004
  end-page: 171
  ident: bib28
  article-title: A meta-analysis of randomised trials suggests a survival benefit for combined radiotherapy and radical cystectomy compared with radical radiotherapy for invasive bladder cancer: Are these data relevant to modern practice?
  publication-title: Clin Oncol (R Coll Radiol)
– volume: 84
  start-page: S119
  year: 2012
  end-page: S120
  ident: bib33
  article-title: Results of the SPARE feasibility study—selective bladder preservation against radical excision in muscle invasive T2/T3 transitional cell carcinoma of the bladder
  publication-title: Int J Radiat Oncol Biol Phys
– volume: 37
  start-page: 184
  year: 2014
  end-page: 189
  ident: bib22
  article-title: Outcomes of radical cystectomy and bladder preservation treatment for muscle-invasive urothelial carcinoma of the bladder
  publication-title: Asian J Surg
– volume: 32
  start-page: 592
  year: 2009
  end-page: 606
  ident: bib10
  article-title: Total cystectomy versus bladder preservation therapy for locally invasive bladder cancer: Effect of combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation
  publication-title: Am J Clin Oncol
– volume: 8
  start-page: 250
  year: 2008
  ident: bib31
  article-title: Muscle invasive bladder cancer in Upper Egypt: The shift in risk factors and tumor characteristics
  publication-title: BMC Cancer
– volume: 138
  start-page: 193
  year: 1991
  end-page: 201
  ident: bib21
  article-title: Treatment of advanced bladder cancer category T2 T3 and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Danish Vesical Cancer Group
  publication-title: Scand J Urol Nephrol Suppl
– volume: 17
  start-page: 2814
  year: 1998
  end-page: 2834
  ident: bib5
  article-title: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints
  publication-title: Stat Med
– volume: 13
  start-page: 428
  year: 2014
  end-page: 437
  ident: bib9
  article-title: Trimodality bladder-sparing approach versus radical cystectomy for invasive bladder cancer
  publication-title: J Radiother Practice
– volume: 187
  start-page: 463
  year: 2012
  end-page: 468
  ident: bib32
  article-title: Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer
  publication-title: J Urol
– volume: 54
  start-page: 136
  year: 1982
  end-page: 151
  ident: bib11
  article-title: Treatment of T3 bladder cancer: Controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy
  publication-title: Br J Urol
– volume: 32
  start-page: 334
  year: 2014
  ident: bib37
  article-title: Comparative effectiveness of radical cystectomy versus bladder-sparing treatment for muscle-invasive urothelial carcinoma: A population-based report
  publication-title: J Clin Oncol
– volume: 65
  start-page: 5
  year: 2015
  end-page: 29
  ident: bib1
  article-title: Cancer statistics, 2015
  publication-title: CA Cancer J Clin
– volume: 39
  start-page: 973
  year: 1977
  end-page: 980
  ident: bib18
  article-title: Bladder cancer: Superiority of preoperative irradiation and cystectomy in clinical stages B2 and C
  publication-title: Cancer
– volume: 327
  start-page: 557
  year: 2003
  end-page: 560
  ident: bib7
  article-title: Measuring inconsistency in meta-analyses
  publication-title: BMJ
– volume: 63
  start-page: 251
  year: 1989
  end-page: 258
  ident: bib27
  article-title: Invasive bladder cancer. Prognostic factors and results of radiotherapy with and without cystectomy
  publication-title: Br J Urol
– volume: 102
  start-page: 284
  year: 2008
  end-page: 290
  ident: bib13
  article-title: Cystectomy in the elderly: Does the survival benefit in younger patients translate to the octogenarians?
  publication-title: BJU Int
– volume: 13
  start-page: e123
  year: 2014
  ident: bib36
  article-title: Long-term outcome following management of muscle invasive bladder cancer: Bladder-sparing Radical Therapy (BRT) and subsequent salvage cystectomy versus immediate primary cystectomy
  publication-title: Eur Urol
– volume: 70
  start-page: 456
  year: 2008
  end-page: 463
  ident: bib17
  article-title: Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center
  publication-title: Int J Radiat Oncol Biol Phys
– volume: 21
  start-page: 3337
  year: 2002
  end-page: 3351
  ident: bib6
  article-title: Aggregate data meta-analysis with time-to-event outcomes
  publication-title: Stat Med
– volume: 193
  start-page: e921
  year: 2015
  ident: bib38
  article-title: MP72-01 Radical cystectomy versus bladder-sparing treatment for patients with muscle-invasive urothelial carcinoma of the urinary bladder: Q comparative effectiveness population-based study
  publication-title: J Urol
– reference: Pokala N, Agarwal P, Kiran RP, et al. Comparative survival following different treatment modalities for stage T2-muscle invasive bladder cancer in octogenarians—a population based study. Presented at the Annual Meeting of the American Urological Association, May 14-19, 2011, Washington, DC.
– reference: Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at:
– volume: 43
  start-page: 246
  year: 2003
  end-page: 257
  ident: bib12
  article-title: A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire
  publication-title: Eur Urol
– volume: 48
  start-page: 202
  year: 2005
  end-page: 205
  ident: bib2
  article-title: Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data
  publication-title: Eur Urol
– volume: 77
  start-page: 119
  year: 2010
  end-page: 124
  ident: bib19
  article-title: A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK
  publication-title: Int J Radiat Oncol Biol Phys
– volume: 106
  start-page: 753
  year: 2010
  end-page: 755
  ident: bib34
  article-title: Life and death of SPARE (selective bladder preservation against radical excision): Reflections on why the SPARE trial closed
  publication-title: BJU Int
– volume: 61
  start-page: 705
  year: 2012
  end-page: 711
  ident: bib3
  article-title: Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: The MGH experience
  publication-title: Eur Urol
– volume: 32
  start-page: 425
  year: 2014
  end-page: 429
  ident: bib23
  article-title: Comparative survival following different treatment modalities for stage T2 bladder cancer in octogenarians
  publication-title: World J Urol
– volume: 24
  start-page: 48
  year: 2008
  end-page: 53
  ident: bib26
  article-title: Outcome following radical cystectomy and bladder-preservation therapy in patients with invasive carcinoma of urinary bladder
  publication-title: Indian J Urol
– volume: 48
  start-page: 239
  year: 2005
  end-page: 245
  ident: bib20
  article-title: Survival after bladder-preservation with brachytherapy versus radical cystectomy; a single institution experience
  publication-title: Eur Urol
– volume: 33
  start-page: 176
  year: 2009
  end-page: 181
  ident: bib30
  article-title: Incidence analyses of bladder cancer in the Nile delta region of Egypt
  publication-title: Cancer Epidemiol
– volume: 93
  start-page: 352
  year: 2009
  end-page: 357
  ident: bib24
  article-title: Brachytherapy versus cystectomy in solitary bladder cancer: A case control, multicentre, East-Netherlands study
  publication-title: Radiother Oncol
– volume: 33
  start-page: 19.e1
  year: 2015
  end-page: 19.e5
  ident: bib14
  article-title: Radical cystectomy vs. chemoradiation in T2-4aN0M0 bladder cancer: A case-control study
  publication-title: Urol Oncol
– volume: 3
  start-page: 81
  year: 2007
  end-page: 85
  ident: bib15
  article-title: A prospective study evaluating surgery and chemo radiation in muscle invasive bladder cancer
  publication-title: J Cancer Res Ther
– volume: 13
  start-page: 353
  year: 2008
  end-page: 358
  ident: bib16
  article-title: Radical therapy for muscle-infiltrating bladder cancer (cystectomy or radiotherapy): Does age affect the final therapeutic benefit for the patient?
  publication-title: J BUON
– volume: 48
  start-page: 587
  year: 1976
  end-page: 594
  ident: bib25
  article-title: The management of deeply infiltrating (T3) bladder carcinoma: Controlled trial of radical radiotherapy versus preoperative radiotherapy and radical cystectomy (first report)
  publication-title: Br J Urol
– volume: 151
  start-page: 264
  year: 2009
  end-page: 269
  ident: bib4
  article-title: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
  publication-title: Ann Intern Med
– reference: . Accessed November 17, 2016.
– volume: 95
  start-page: 387
  year: 2015
  end-page: 396
  ident: bib29
  article-title: Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials
  publication-title: Crit Rev Oncol Hematol
– volume: 187
  start-page: 463
  year: 2012
  ident: 10.1016/j.ijrobp.2016.11.056_bib32
  article-title: Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer
  publication-title: J Urol
  doi: 10.1016/j.juro.2011.09.159
– volume: 65
  start-page: 5
  year: 2015
  ident: 10.1016/j.ijrobp.2016.11.056_bib1
  article-title: Cancer statistics, 2015
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21254
– volume: 93
  start-page: 352
  year: 2009
  ident: 10.1016/j.ijrobp.2016.11.056_bib24
  article-title: Brachytherapy versus cystectomy in solitary bladder cancer: A case control, multicentre, East-Netherlands study
  publication-title: Radiother Oncol
  doi: 10.1016/j.radonc.2009.04.020
– volume: 106
  start-page: 753
  year: 2010
  ident: 10.1016/j.ijrobp.2016.11.056_bib34
  article-title: Life and death of SPARE (selective bladder preservation against radical excision): Reflections on why the SPARE trial closed
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2010.09537.x
– volume: 3
  start-page: 81
  year: 2007
  ident: 10.1016/j.ijrobp.2016.11.056_bib15
  article-title: A prospective study evaluating surgery and chemo radiation in muscle invasive bladder cancer
  publication-title: J Cancer Res Ther
  doi: 10.4103/0973-1482.34684
– volume: 21
  start-page: 3337
  year: 2002
  ident: 10.1016/j.ijrobp.2016.11.056_bib6
  article-title: Aggregate data meta-analysis with time-to-event outcomes
  publication-title: Stat Med
  doi: 10.1002/sim.1303
– volume: 13
  start-page: 428
  year: 2014
  ident: 10.1016/j.ijrobp.2016.11.056_bib9
  article-title: Trimodality bladder-sparing approach versus radical cystectomy for invasive bladder cancer
  publication-title: J Radiother Practice
  doi: 10.1017/S1460396914000107
– volume: 32
  start-page: 425
  year: 2014
  ident: 10.1016/j.ijrobp.2016.11.056_bib23
  article-title: Comparative survival following different treatment modalities for stage T2 bladder cancer in octogenarians
  publication-title: World J Urol
  doi: 10.1007/s00345-013-1123-2
– volume: 33
  start-page: 176
  year: 2009
  ident: 10.1016/j.ijrobp.2016.11.056_bib30
  article-title: Incidence analyses of bladder cancer in the Nile delta region of Egypt
  publication-title: Cancer Epidemiol
  doi: 10.1016/j.canep.2009.08.008
– volume: 32
  start-page: 334
  year: 2014
  ident: 10.1016/j.ijrobp.2016.11.056_bib37
  article-title: Comparative effectiveness of radical cystectomy versus bladder-sparing treatment for muscle-invasive urothelial carcinoma: A population-based report
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2014.32.4_suppl.334
– volume: 327
  start-page: 557
  year: 2003
  ident: 10.1016/j.ijrobp.2016.11.056_bib7
  article-title: Measuring inconsistency in meta-analyses
  publication-title: BMJ
  doi: 10.1136/bmj.327.7414.557
– volume: 48
  start-page: 239
  year: 2005
  ident: 10.1016/j.ijrobp.2016.11.056_bib20
  article-title: Survival after bladder-preservation with brachytherapy versus radical cystectomy; a single institution experience
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2005.03.022
– volume: 17
  start-page: 2814
  year: 1998
  ident: 10.1016/j.ijrobp.2016.11.056_bib5
  article-title: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints
  publication-title: Stat Med
  doi: 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
– volume: 95
  start-page: 387
  year: 2015
  ident: 10.1016/j.ijrobp.2016.11.056_bib29
  article-title: Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2015.04.006
– volume: 16
  start-page: 166
  year: 2004
  ident: 10.1016/j.ijrobp.2016.11.056_bib28
  article-title: A meta-analysis of randomised trials suggests a survival benefit for combined radiotherapy and radical cystectomy compared with radical radiotherapy for invasive bladder cancer: Are these data relevant to modern practice?
  publication-title: Clin Oncol (R Coll Radiol)
  doi: 10.1016/j.clon.2003.10.001
– volume: 77
  start-page: 119
  year: 2010
  ident: 10.1016/j.ijrobp.2016.11.056_bib19
  article-title: A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2009.04.050
– volume: 138
  start-page: 193
  year: 1991
  ident: 10.1016/j.ijrobp.2016.11.056_bib21
  publication-title: Scand J Urol Nephrol Suppl
  doi: 10.1080/21681805.1991.12068888
– ident: 10.1016/j.ijrobp.2016.11.056_bib35
  doi: 10.1016/j.juro.2011.02.1879
– volume: 43
  start-page: 246
  year: 2003
  ident: 10.1016/j.ijrobp.2016.11.056_bib12
  article-title: A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire
  publication-title: Eur Urol
  doi: 10.1016/S0302-2838(02)00581-X
– volume: 48
  start-page: 587
  year: 1976
  ident: 10.1016/j.ijrobp.2016.11.056_bib25
  article-title: The management of deeply infiltrating (T3) bladder carcinoma: Controlled trial of radical radiotherapy versus preoperative radiotherapy and radical cystectomy (first report)
  publication-title: Br J Urol
  doi: 10.1111/j.1464-410X.1976.tb06705.x
– volume: 13
  start-page: 353
  year: 2008
  ident: 10.1016/j.ijrobp.2016.11.056_bib16
  article-title: Radical therapy for muscle-infiltrating bladder cancer (cystectomy or radiotherapy): Does age affect the final therapeutic benefit for the patient?
  publication-title: J BUON
– volume: 61
  start-page: 705
  year: 2012
  ident: 10.1016/j.ijrobp.2016.11.056_bib3
  article-title: Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: The MGH experience
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2011.11.010
– volume: 193
  start-page: e921
  year: 2015
  ident: 10.1016/j.ijrobp.2016.11.056_bib38
  article-title: MP72-01 Radical cystectomy versus bladder-sparing treatment for patients with muscle-invasive urothelial carcinoma of the urinary bladder: Q comparative effectiveness population-based study
  publication-title: J Urol
  doi: 10.1016/j.juro.2015.02.2635
– volume: 63
  start-page: 251
  year: 1989
  ident: 10.1016/j.ijrobp.2016.11.056_bib27
  article-title: Invasive bladder cancer. Prognostic factors and results of radiotherapy with and without cystectomy
  publication-title: Br J Urol
  doi: 10.1111/j.1464-410X.1989.tb05185.x
– volume: 84
  start-page: S119
  year: 2012
  ident: 10.1016/j.ijrobp.2016.11.056_bib33
  article-title: Results of the SPARE feasibility study—selective bladder preservation against radical excision in muscle invasive T2/T3 transitional cell carcinoma of the bladder
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2012.07.211
– ident: 10.1016/j.ijrobp.2016.11.056_bib8
– volume: 39
  start-page: 973
  year: 1977
  ident: 10.1016/j.ijrobp.2016.11.056_bib18
  article-title: Bladder cancer: Superiority of preoperative irradiation and cystectomy in clinical stages B2 and C
  publication-title: Cancer
  doi: 10.1002/1097-0142(197702)39:2+<973::AID-CNCR2820390737>3.0.CO;2-O
– volume: 13
  start-page: e123
  year: 2014
  ident: 10.1016/j.ijrobp.2016.11.056_bib36
  article-title: Long-term outcome following management of muscle invasive bladder cancer: Bladder-sparing Radical Therapy (BRT) and subsequent salvage cystectomy versus immediate primary cystectomy
  publication-title: Eur Urol
  doi: 10.1016/S1569-9056(14)60124-X
– volume: 48
  start-page: 202
  year: 2005
  ident: 10.1016/j.ijrobp.2016.11.056_bib2
  article-title: Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2005.04.006
– volume: 102
  start-page: 284
  year: 2008
  ident: 10.1016/j.ijrobp.2016.11.056_bib13
  article-title: Cystectomy in the elderly: Does the survival benefit in younger patients translate to the octogenarians?
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2008.07636.x
– volume: 37
  start-page: 184
  year: 2014
  ident: 10.1016/j.ijrobp.2016.11.056_bib22
  article-title: Outcomes of radical cystectomy and bladder preservation treatment for muscle-invasive urothelial carcinoma of the bladder
  publication-title: Asian J Surg
  doi: 10.1016/j.asjsur.2014.01.010
– volume: 32
  start-page: 592
  year: 2009
  ident: 10.1016/j.ijrobp.2016.11.056_bib10
  article-title: Total cystectomy versus bladder preservation therapy for locally invasive bladder cancer: Effect of combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation
  publication-title: Am J Clin Oncol
  doi: 10.1097/COC.0b013e318199fb42
– volume: 151
  start-page: 264
  year: 2009
  ident: 10.1016/j.ijrobp.2016.11.056_bib4
  article-title: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-151-4-200908180-00135
– volume: 24
  start-page: 48
  year: 2008
  ident: 10.1016/j.ijrobp.2016.11.056_bib26
  article-title: Outcome following radical cystectomy and bladder-preservation therapy in patients with invasive carcinoma of urinary bladder
  publication-title: Indian J Urol
  doi: 10.4103/0970-1591.38603
– volume: 70
  start-page: 456
  year: 2008
  ident: 10.1016/j.ijrobp.2016.11.056_bib17
  article-title: Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2007.06.030
– volume: 8
  start-page: 250
  year: 2008
  ident: 10.1016/j.ijrobp.2016.11.056_bib31
  article-title: Muscle invasive bladder cancer in Upper Egypt: The shift in risk factors and tumor characteristics
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-8-250
– volume: 54
  start-page: 136
  year: 1982
  ident: 10.1016/j.ijrobp.2016.11.056_bib11
  article-title: Treatment of T3 bladder cancer: Controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy
  publication-title: Br J Urol
  doi: 10.1111/j.1464-410X.1982.tb13537.x
– volume: 33
  start-page: 19.e1
  year: 2015
  ident: 10.1016/j.ijrobp.2016.11.056_bib14
  article-title: Radical cystectomy vs. chemoradiation in T2-4aN0M0 bladder cancer: A case-control study
  publication-title: Urol Oncol
  doi: 10.1016/j.urolonc.2014.09.014
– reference: 29280469 - Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):757. doi: 10.1016/j.ijrobp.2017.07.001.
– reference: 29396699 - Strahlenther Onkol. 2018 Apr;194(4):358-359. doi: 10.1007/s00066-018-1274-6.
– reference: 29280470 - Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):757-758. doi: 10.1016/j.ijrobp.2017.07.002.
SSID ssj0001174
Score 2.504069
SecondaryResourceType review_article
Snippet To perform a comprehensive comparison of overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), and treatment-related...
Purpose To perform a comprehensive comparison of overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), and treatment-related...
To perform a comprehensive comparison of overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), and treatment-related...
Purpose: To perform a comprehensive comparison of overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), and...
SourceID osti
proquest
pubmed
crossref
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1002
SubjectTerms Aged
Aged, 80 and over
BLADDER
Chemoradiotherapy - mortality
Chemoradiotherapy - statistics & numerical data
CHEMOTHERAPY
Combined Modality Therapy
Cystectomy - mortality
Cystectomy - statistics & numerical data
Disease-Free Survival
Female
Hematology, Oncology and Palliative Medicine
Humans
Male
Middle Aged
Neoplasm Invasiveness
NEOPLASMS
Postoperative Complications - mortality
Postoperative Complications - prevention & control
Prevalence
Radiation Injuries - mortality
Radiation Injuries - prevention & control
RADICALS
Radiology
RADIOLOGY AND NUCLEAR MEDICINE
RADIOTHERAPY
Risk Factors
Survival Rate
Treatment Outcome
Urinary Bladder Neoplasms - mortality
Urinary Bladder Neoplasms - therapy
Title Radical Cystectomy Compared to Combined Modality Treatment for Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0360301616335490
https://www.clinicalkey.es/playcontent/1-s2.0-S0360301616335490
https://dx.doi.org/10.1016/j.ijrobp.2016.11.056
https://www.ncbi.nlm.nih.gov/pubmed/28332983
https://www.proquest.com/docview/1880469693
https://www.osti.gov/biblio/22649890
Volume 97
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9NAEF2FVEJcEN8NFLRI3CpH9nrt2NxCBApU4dCGNrfVer2WGpUYJQ6HnPmn_BFmsru20w-19GJZkdd2PM87b8ZvZgn5wPxcJn4qIcjJE49nnHvo570i8HMVsEzmIdY7T77H4x_82yyadTp_W6qldZX11ebaupL7WBV-A7tilex_WLY-KfwA-2Bf2IKFYXsnGx9L85VlhO2YVVX-tO83asqBU8I-xL2wPylzQ7entawc1YWT9QpO6H1d_JZbEfunC5yGlocjRMLS1KyfNJ2ebQ_-rTJDV9Jz_Uza_HY3wdhqS7HEHgiGnS5UXSGTNcUyJsVSM_xTXORpVZnPUae4RHQtBTmzKe4x0FpMdzdJ9c2mtAnaRqaJYqNzszK8LRE4HPbbuQ7wn41EZpuAc0U4OxpR8MHgSvzAdtQ283gySD2gUrP2RG-EwBbQUWvWxja0LQYAnMu_1ruYRMe8fz5flhk2Ow3iPraAjS41897SgxO8L7wtYLwhROH-A7LHIJaByXhveHR8dlQThsA2C3f_w1V4bmWIV691E4PqluAUbg6UtoRp-oQ8tpEOHRrYPiUdvXhGHk6sluM5-WPRSxv0UodeWpXUoZc69NIavRTQSy-hl1r0UoPej3RIG-xSg10K2KU72H1Bpl8-T0djz64J4qko5pWXxpFkRZzDNKCiSGtg45pHPMgUBy5d-DpWMk90wUKpc6C3mR-GRQ7H-MpnWRS-JN0FQHGfUKZipgZFxuI042leJGnEtRrwRLKMyWDQI6F7zELZfvm4bMuFcMLIuTDGEWgcCKUFGKdHvHrUL9Mv5pbjI2dB4WqhwXsLgNwt4wbXjdMr-2avRCBWTPjiCgzbIy3LNuz5Dtc8QIjhKGwwrVCJB8OwFD9N8MTvHfQE-Cj88CgXulzDrQBJ4HEap2GPvDKYrB8OhDchS5Pw9b1v6w151MwVB6RbLdf6LUQKVfbOvmn_AE8rGAU
linkProvider Library Specific Holdings
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Radical+Cystectomy+Compared+to+Combined+Modality+Treatment+for+Muscle-Invasive+Bladder+Cancer%3A+A+Systematic+Review+and+Meta-Analysis&rft.jtitle=International+journal+of+radiation+oncology%2C+biology%2C+physics&rft.au=Vashistha%2C+Vishal&rft.au=Wang%2C+Hanzhang&rft.au=Mazzone%2C+Andrew&rft.au=Liss%2C+Michael+A.&rft.date=2017-04-01&rft.pub=Elsevier+Inc&rft.issn=0360-3016&rft.eissn=1879-355X&rft.volume=97&rft.issue=5&rft.spage=1002&rft.epage=1020&rft_id=info:doi/10.1016%2Fj.ijrobp.2016.11.056&rft.externalDocID=S0360301616335490
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F03603016%2FS0360301616X00211%2Fcov150h.gif